Clinical Study Results
The table below shows the serious adverse reactions that happened in at least 2 participants
during the study. There were other serious adverse reactions that happened during the study, but
these happened in fewer participants.
Most common serious adverse reactions during the study
Group 1 Group 2 Group 3
(durvalumab and (durvalumab alone) (SOC treatment)
tremelimumab) out of out of out of
246 participants 237 participants 240 participants
Swelling in the lungs 0.8% (2) 1.3% (3) 0.0% (0)
Pneumonia 0.8% (2) 0.0% (0) 0.8% (2)
Anemia (decrease in the
amount of red blood 1.2% (3) 0.0% (0) 0.0% (0)
cells in the blood)
Diarrhea 0.8% (2) 0.0% (0) 0.4% (1)
An unknown serious
0.4% (1) 0.4% (1) 0.0% (0)
adverse reaction
Increase in level of ADH 0.0% (0) 0.8% (2) 0.0% (0)
Decrease in neutrophils,
which are a type of white
0.0% (0) 0.0% (0) 0.8% (2)
blood cell (may increase
the risk of infection)
How many participants had adverse reactions?
The table below shows how many participants had adverse reactions during the study.
Adverse reactions during the study
Group 1 Group 2 Group 3
(durvalumab and (durvalumab alone) (SOC treatment)
tremelimumab) out of out of out of
246 participants 237 participants 240 participants
How many participants
had adverse reactions 61.0% (150) 57.4% (136) 82.1% (197)
during the study?
How many participants
had serious adverse
11.8% (29) 7.2% (17) 6.3% (15)
reactions during the
study?
How many participants
stopped treatment
4.1% (10) 3.8% (9) 4.2% (10)
because of adverse
reactions?
9